




Searching News Database: lupus nephritis
HSMN NewsFeed - 3 Aug 2023
Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors
Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors
HSMN NewsFeed - 26 Jan 2022
Kyverna Therapeutics Closes $85 Million Series B Financing led by Northpond Ventures
Kyverna Therapeutics Closes $85 Million Series B Financing led by Northpond Ventures
HSMN NewsFeed - 17 Dec 2020
FDA Approves GSK's BENLYSTA as the First Medicine for Adult Patients with Active Lupus Nephritis in the US
FDA Approves GSK's BENLYSTA as the First Medicine for Adult Patients with Active Lupus Nephritis in the US
HSMN NewsFeed - 6 Nov 2013
Aurinia Appoints Accomplished Biotech and Pharma Industry Veteran, Stephen W. Zaruby, as President & CEO
Aurinia Appoints Accomplished Biotech and Pharma Industry Veteran, Stephen W. Zaruby, as President & CEO
HSMN NewsFeed - 27 Dec 2012
Isotechnika Announces That Lux Biosciences' Phase 3 Uveitis Study Did Not Meet Primary Endpoint
Isotechnika Announces That Lux Biosciences' Phase 3 Uveitis Study Did Not Meet Primary Endpoint
HSMN NewsFeed - 14 Jul 2011
GlaxoSmithKline and Human Genome Sciences Receive European Authorization for BENLYSTA(R) (Belimumab)
GlaxoSmithKline and Human Genome Sciences Receive European Authorization for BENLYSTA(R) (Belimumab)
HSMN NewsFeed - 7 Dec 2010
La Jolla Pharmaceutical Company Announces Appointment of Dr. Bertrand C. Liang to Board of Directors
La Jolla Pharmaceutical Company Announces Appointment of Dr. Bertrand C. Liang to Board of Directors
HSMN NewsFeed - 7 Sep 2010
La Jolla Pharmaceutical Company Provides Update on Search for Clinical Products to In-License or Acquire
La Jolla Pharmaceutical Company Provides Update on Search for Clinical Products to In-License or Acquire
HSMN NewsFeed - 11 Mar 2009
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
HSMN NewsFeed - 18 Sep 2008
Laquinimod Demonstrated Significant and Sustained Impact on Multiple Sclerosis Disease Activity
Laquinimod Demonstrated Significant and Sustained Impact on Multiple Sclerosis Disease Activity
HSMN NewsFeed - 16 Jul 2008
Teva Enrolls Patients for a Second Large Global Phase III Trial of Oral Laquinimod
Teva Enrolls Patients for a Second Large Global Phase III Trial of Oral Laquinimod
HSMN NewsFeed - 5 Jun 2008
Merck Serono Announces Initiation of Second Phase II/III Clinical Study of Atacicept in Lupus
Merck Serono Announces Initiation of Second Phase II/III Clinical Study of Atacicept in Lupus
HSMN NewsFeed - 27 Jun 2007
Aspreva and Roche announce preliminary results for phase III study evaluating CellCept in lupus nephritis
Aspreva and Roche announce preliminary results for phase III study evaluating CellCept in lupus nephritis
HSMN NewsFeed - 6 Jun 2007
Aspreva announces Fast-Track designation granted by the FDA for CellCept in lupus nephritis
Aspreva announces Fast-Track designation granted by the FDA for CellCept in lupus nephritis
HSMN NewsFeed - 29 Sep 2006
FDA Approves Two New Indications for Rituxan(R) in Patients With Non-Hodgkin's Lymphoma
FDA Approves Two New Indications for Rituxan(R) in Patients With Non-Hodgkin's Lymphoma
Additional items found! 7

Members Archive contains
7 additional stories matching:
lupus nephritis
(Password required)
lupus nephritis
(Password required)